Document:

EX-10.10

 Exhibit 10.10 

EXCLUSIVE LICENSE AGREEMENT 

This EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is dated as of the
11th day of May, 2020 (the “Effective Date”), by and between BOSTON SCIENTIFIC CORPORATION, a Delaware corporation, on behalf of itself and its affiliates
(“Licensor”), and Minerva Surgical, Inc., a Delaware corporation (“Licensee”). 
 WHEREAS, Licensor
and Licensee have entered into a certain Asset Purchase Agreement, dated as of April 28, 2020 (the “Purchase Agreement”), pursuant to which, as of the Effective Date, Licensee is purchasing from Licensor all right, title and
interest in and to the Business Transferred Intellectual Property (as such term is defined in the Purchase Agreement); 
 WHEREAS,
Licensor has agreed to grant to Licensee an exclusive, royalty-free license under the Licensed Patents (as defined herein) and other Business Licensed Intellectual Property (as such term is defined in the Purchase Agreement) for the limited purposes
described, and in accordance with the terms and conditions set forth, in this Agreement; and 
 WHEREAS, Licensee desires to obtain
such an exclusive license from Licensor under such Licensed Patents and Business Licensed Intellectual Property for the limited purposes described, and in accordance with the terms and conditions set forth, in this Agreement. 

NOW, THEREFORE, in consideration of the premises and mutual promises and agreements hereinafter set forth, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
 ARTICLE I.

 DEFINITIONS 

Section 1.01    Certain Defined Terms. The following initially capitalized terms, when
used herein, have the meanings set forth below. Initially capitalized terms used herein and not otherwise defined shall have the meanings assigned thereto in the Purchase Agreement. 

“Confidential Information” means any and all confidential or proprietary information disclosed by or on behalf of a party or
any of its Representatives (“Disclosing Party”) to the other party or any of its Representatives (“Receiving Party”) under this Agreement, including information regarding Disclosing Party’s past, present or
future research, technology, know-how, ideas, concepts, designs, products, markets, computer programs, prototypes, processes, machines, manufacture, compositions of matter, business plans and operations,
technical information, drawings, specifications, and the like, except information which is: (a) at the time of disclosure, or thereafter becomes, a part of the public domain through no act or omission by Receiving Party or its Representatives;
(b) lawfully in the possession of Receiving Party prior to disclosure by or on behalf of Disclosing Party as shown by Receiving Party’s written records; (c) lawfully disclosed to Receiving Party by a third party which did not acquire
the same under an obligation of confidentiality from or through Disclosing Party as shown by written records; or (d) independently developed by Receiving Party without use of or reference to Disclosing Party’s Confidential Information, as
shown by Receiving Party’s written records. For clarity, and notwithstanding anything to the contrary herein, all non-public subject matter claimed, disclosed or otherwise embodied in the Licensed Patents
or other Business Licensed Intellectual Property, as well as the terms of this Agreement, shall be the Confidential Information of each party. 

 “Licensee Field” means all uses and applications relating to the
intrauterine resection of tissue or the intrauterine ablation of tissue. 
 “Licensed Patent(s)” means: (a) the
patents and patent application(s) listed or described (or purported to be listed or described) in Section 3.08(a)(i) of the Seller Disclosure Schedule of the Purchase Agreement; (b) any patent application(s) filed as a continuation,
division, or continuation-in-part of the patents or patent application(s) described in clause (a); (c) patents issuing from the patent application(s) described in
clauses (a)-(b) and any extensions, renewals, reissues, revivals and reexaminations of patents described in clauses (a)-(b); and (d) any foreign counterpart to the patents and patent application(s) described in clauses (a)-(c) (including
continuations, divisions, or continuations-in-part of such patent applications), patents issuing therefrom and extensions, renewals, reissues, revivals and
reexaminations thereof. 
 “Licensed Products” means any product, part or other material, process or service that
incorporates, embodies or otherwise uses, in whole or in part, any Business Licensed Intellectual Property. 
 “Licensor
Field” means all uses outside the Licensee Field. For clarity, the Licensor Field does not include the commercialization or other exploitation of any fluid management product that (a) is compatible for use with the SymphionTM tissue removal system, and/or (b) incorporates, is covered by or otherwise embodies any Business Intellectual Property for intrauterine use or any gynecologic indication. 

“Representatives” means a party’s or, solely with respect to Licensee, its sublicensee’s employees, officers,
directors, Affiliates, agents, successors and assigns. 
 The following table sets forth certain other defined terms and the Section of the
Agreement in which the meaning of each such term appears: 
  

			
	 	  	Section
	 “Agreement”
	  	Preamble
	 “Disclosing Party”
	  	1.01
	 “Effective Date”
	  	Preamble
	 “Licensee”
	  	Preamble
	 “Licensee Indemnitees”
	  	7.02
	 “Licensor”
	  	Preamble
	 “Licensor Indemnitees”
	  	7.01
	 “Purchase Agreement”
	  	Recitals
	 “Receiving Party”
	  	1.01

  
 2 

 ARTICLE II. 

GRANT OF RIGHTS 

Section 2.01    Licensed Patents. Subject to the terms and conditions of this Agreement,
Licensor hereby grants to Licensee, and Licensee hereby accepts from Licensor, an exclusive, non-transferable (except as expressly permitted in Section 8.05) worldwide, royalty-free,
fully paid-up, perpetual and irrevocable right and license, including the right to sublicense in accordance with Section 2.02 below, under the Licensed Patents and other Business
Licensed Intellectual Property to develop, have developed, make, have made, use, offer for sale, sell, have sold and import products and otherwise exploit the Licensed Patents and other Business Licensed Intellectual Property within the Licensee
Field. Licensee shall have the right to exercise such license through its Affiliates, provided that Licensee shall be responsible for its Affiliates’ compliance with the terms and conditions of this Agreement including all relevant
restrictions, limitations and obligations. 
 Section 2.02    Sublicenses. Licensee
shall have the right to sublicense its rights under the Licensed Patents and other Business Licensed Intellectual Property pursuant to Section 2.01 to third parties through multiple tiers of sublicensees, provided that
(a) Licensee shall notify Licensor in writing of all such sublicenses and Licensee shall enter into a written agreement with each such sublicensee, a signed copy of which shall be provided to Licensor within thirty (30) days of execution
(which copy may be redacted of information not necessary to determine Licensee’s compliance with this Agreement); and (b) each such sublicense agreement shall be consistent with the terms and conditions of this Agreement. Licensee shall be
responsible and liable for any breaches of this Agreement by its sublicensees or Representatives. 

Section 2.03    Retained Rights. Nothing in this Agreement shall be construed to
confer any rights upon Licensee by implication, estoppel or otherwise to any technology or to patent rights of Licensor or any other entity, other than the express licenses to the Licensed Patents as set forth in
Section 2.01. Title to the Licensed Patents and other Business Licensed Intellectual Property will at all times remain vested in Licensor and Licensor retains the right (a) to grant licenses to other parties with
respect to the Licensed Patents, and (b) to use the Licensed Patents in any manner and for any purpose which Licensor deems fit, in each case (a) and (b) solely to the extent outside the Licensee Field. Licensor (on behalf of itself and
its licensors) retains all rights not expressly granted herein. 
 Section 2.04    Licensee
Improvements. 
 (a)    Subject to the terms and conditions of this Agreement, Licensee hereby grants to Licensor,
and Licensor hereby accepts from Licensor, a non-exclusive, worldwide, royalty-free, fully paid-up, perpetual and irrevocable,
non-transferable (except as expressly permitted in Section 8.05), right and license, including the right to sublicense (in accordance with Section 2.04(b)),
under any and all Intellectual Property that covers, relates to or is embodied in any improvement, enhancement or modification made by or on behalf of Licensee or its sublicensees to the Licensed Patents (“Licensee Improvements”),
to (a) use, reproduce, prepare derivative works from, distribute, publicly perform, publicly display or otherwise exploit such Licensee Improvements, and (b) use, develop, make, have made, use, have used, distribute, promote, offer for
sale, sell, have sold, import and export any products or services of Licensor or its Affiliates; 

  
 3 

 
in each case ((a) and (b)) solely in the Licensor Field. Licensor shall have the right to exercise such license through its Affiliates, provided that Licensor shall be responsible for its
Affiliates’ compliance with the terms and conditions of this Agreement including all relevant restrictions, limitations and obligations. 

(b)    Licensor’s right to sublicense its rights under such Licensee Improvements pursuant to
Section 2.04(a) (i) is limited to instances in which Licensor sells, transfers or divests one or more products or product lines to which this license may relate and wishes to grant the acquirer of such asset(s) a
sublicense hereunder, and (ii) is subject to the requirements that (a) Licensor shall notify Licensee in writing of all such sublicenses and Licensor shall enter into a written agreement with each such sublicensee, a signed copy of which
shall be provided to Licensee within ten (10) days of execution; and (b) Licensor shall include in each such sublicense agreement provisions at least as protective of Licensee and its rights in such Licensee Improvements as the terms and
conditions of this Agreement. All sublicenses shall terminate automatically upon expiration of the license granted to Licensor herein. Licensor shall be responsible and liable for any breaches of this Agreement by its sublicensees. 

Section 2.05    Confirmatory License. Licensor shall, if requested to do so by Licensee,
promptly enter into one or more confirmatory license agreements in such form as may be reasonably requested by Licensee for purposes of recording the licenses and rights granted under this Agreement with such Governmental Authorities, including
patent and trademark offices, as Licensee deems appropriate so long as any rights of the Licensor are not negatively affected. 
 ARTICLE
III. 
 REPRESENTATIONS AND WARRANTIES 

Section 3.01    General Representations. Each of Licensee and Licensor hereby represents
and warrants to the other party that: (a) it is an entity duly organized and validly existing under the laws of the applicable state of its formation, and has all requisite power and authority to execute, deliver and perform this Agreement and
to consummate the transactions contemplated hereby; (b) this Agreement has been duly authorized, executed and delivered by such party and it constitutes the legal, valid and binding obligations of such party, and it is enforceable against such
party in accordance with its terms, except to the extent such enforceability may be limited by bankruptcy, reorganization, insolvency or similar laws of general applicability governing the enforcement of the rights of creditors; and (c) neither
the execution, delivery and performance of this Agreement nor the consummation by such party of the transactions contemplated hereby, does or will violate or conflict with or constitute a default under any contractual obligation of such party, or
any judgment, order or decree applicable to, or binding upon, such party. 

Section 3.02    Licensor Representations, Warranties and Covenants. Licensor hereby
further represents, warrants and covenants to Licensee that Licensor has not granted as of the Effective Date and will not grant during the term of this Agreement rights to any third party under the Licensed Patents or other Business Licensed
Intellectual Property that conflict with the rights granted to Licensee hereunder. In addition, Licensor shall (a) use commercially reasonable efforts to comply with all terms and conditions of the Licensed Intellectual Property Agreements (as
defined in the Purchase Agreement) pursuant to which Licensor or its Affiliates 

  
 4 

 
was licensed, assigned or otherwise acquired from a third party rights in or to any Business Licensed Intellectual Property relating to the Licensee Field (collectively, the “In-License Agreements”), (b) not voluntarily terminate any of Licensor’s or its Affiliates’ rights or licenses under the In-License Agreements relating to
any Licensed Patents or other Business Licensed Intellectual Property in the Licensee Field, (c) not amend the In-License Agreements in any way that would limit, modify or restrict Licensee’s rights
and licenses hereunder or increase or modify Licensee’s obligations hereunder, or (d) not waive any rights under the In-License Agreements in a manner that would adversely affect the rights and
licenses granted to or obligations undertaken by Licensee hereunder, except, in each case (a)-(d), with Licensee’s prior written consent. 

Section 3.03    Disclaimer. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES SET FORTH IN
SECTION 3.01 AND SECTION 3.02 OF THIS AGREEMENT, AND THE REPRESENTATIONS AND WARRANTIES SET FORTH IN THE PURCHASE AGREEMENT AND OTHER ANCILLARY AGREEMENTS, LICENSOR AND LICENSEE EACH MAKES NO OTHER EXPRESS OR IMPLIED WARRANTY AS TO THE
LICENSED PATENTS OR THE LICENSED PRODUCTS OR THE SUBJECT MATTER OF THIS AGREEMENT, AND HEREBY DISCLAIMS THE SAME. 

Section 3.04    Export. Licensee acknowledges and agrees that it shall not export or re-export, directly or indirectly (including via remote access), the Licensed Patents or any Licensed Products or other information or materials it receives pursuant to this Agreement to any country for which the
United States or any other relevant jurisdiction requires any export license or other governmental approval at the time of export without first obtaining such license or approval. 

ARTICLE IV. 

CONFIDENTIALITY 

Section 4.01    Nondisclosure and Nonuse Obligations. Receiving Party shall not, without
the prior consent of Disclosing Party, disclose any of Disclosing Party’s Confidential Information to anyone for any reason at any time or use any of Disclosing Party’s Confidential Information for any purpose except to perform its
obligations or exercise its rights set forth in this Agreement. If Receiving Party believes in good faith that it is required by the law of any relevant jurisdiction or pursuant to an order of a court of competent jurisdiction or that of a competent
Governmental Authority to disclose any of Disclosing Party’s Confidential Information, it shall provide notice to Disclosing Party, to the extent possible, prior to making such disclosure, so as to allow Disclosing Party time to undertake legal
or other action to prevent such disclosure or otherwise obtain confidential treatment of such disclosure. In no such event will Receiving Party disclose any of Disclosing Party’s Confidential Information that Receiving Party is not compelled to
disclose by law, and Receiving Party will exercise reasonable efforts to obtain assurance that confidential treatment will be accorded to any of Disclosing Party’s Confidential Information so disclosed. 

Section 4.02    Representatives. Except as expressly provided in this Agreement,
Receiving Party shall limit dissemination of Disclosing Party’s Confidential Information to only those of Receiving Party’s Representatives having a “need to know”, advise each such Representative who receives Disclosing
Party’s Confidential Information that such information 

  
 5 

 
is confidential, and require each such Representative (other than attorneys and other agents who are already under a professional duty of confidentiality) to sign and comply with a written
agreement obligating it/he/she to observe all of Receiving Party’s obligations hereunder relating to confidentiality and non-disclosure. Each party further acknowledges that the Disclosing Party’s
disclosure of Disclosing Party’s Confidential Information (including that which is a process, machine, manufacture, or composition of matter) is not intended to be an offer for sale or public use. Receiving Party shall not, by virtue of this
Agreement, obtain any title to, or any interest or license in, any of Disclosing Party’s Confidential Information, except as expressly provided for in this Agreement. 

Section 4.03    Permitted Disclosures. Receiving Party may further disclose Confidential
Information of the Disclosing Party to the extent that such disclosure is: 
 (a)    made by or on behalf of Receiving
Party to a Governmental Authority as may be reasonably necessary or useful for purposes of obtaining or enforcing a patent in accordance with this Agreement; provided, however, that reasonable measures shall be taken to assure confidential treatment
of such information (to the extent such protection is available); 
 (b)    made by or on behalf of Receiving Party to
potential or actual investors or acquirers as may be reasonably necessary in connection with their evaluation of such potential or actual investment or acquisition; provided, however, that such Persons shall be subject to obligations of
confidentiality and non-use with respect to such Confidential Information substantially similar to the obligations of confidentiality and non-use of Receiving Party
pursuant to this Article IV; and 
 (c)    made by or on behalf of Licensee, its sublicensees or their
Representatives to Governmental Authorities as may be reasonably necessary in connection with any filing, application or request for Registration of any Product. 

Section 4.04    Third Party Information. Neither party shall, nor shall it permit any of
its Representatives, to disclose to the other party any confidential or proprietary information belonging to any third party without the prior written consent of such party. 

ARTICLE V. 
 PATENT
PROSECUTION; INFRINGEMENT 
 Section 5.01    Prosecution. As between the Parties,
except as provided herein, Licensor shall, at its own expense, control and be solely responsible for the prosecution and maintenance of the Licensed Patents. Licensee shall cooperate, at Licensor’s reasonable request, with the prosecution and
maintenance of the Licensed Patents and in any other related proceedings before a patent official or office. Licensor shall consult with and keep Licensee reasonably informed on the preparation, filing, prosecution and maintenance of the Licensed
Patents (including notifying Licensee of all material developments with respect to such activities on a worldwide basis in a timely manner), furnish Licensee with copies of each document relevant to such preparation, filing, prosecution and
maintenance to allow for review and comment by Licensee reasonably (but not less than thirty (30) days) in advance of submission, and shall consider in good faith timely comments from Licensee; provided that Licensor shall have the final
decision-making 

  
 6 

 
authority over such preparation, filing, prosecution and maintenance. If Licensee reasonably requests that Licensor take steps to prepare, file, prosecute or maintain any Licensed Patent(s) and
Licensor declines or otherwise fails to do so within a reasonable time period, then Licensee shall be entitled to take such reasonable action at its own expense on behalf of Licensor; provided, however, that all such Licensed Patent(s) shall
continue to be owned by Licensor. Notwithstanding the foregoing or anything to the contrary herein, if Licensor determines not to prosecute or otherwise abandon any Licensed Patent(s), Licensor shall provide Licensee with prompt written notice of
such determination (which notice shall be given at least sixty (60) days prior to the next deadline for any action that may be taken with respect to such Licensed Patent(s)), and, at Licensee’s request, assign to Licensee all right, title
and interest in and to such Licensed Patent(s)) without charge. After assignment to Licensee, Licensee and Licensor shall amend and execute an amendment to the Non-Exclusive License Agreement (executed by both
parties as of even date herewith) to include the newly assigned Licensed Patent(s). 

Section 5.02    Infringement. Licensor shall have the sole right, but not the obligation,
to bring suit against any Person for infringement or misappropriation of the Licensed Patents outside of the Licensee Field, and to control such suit at its own expense; provided, in each case, that Licensee does not provide reasonable rationale for
not doing so (including a substantive concern regarding counterclaims of invalidity or unenforceability of any Licensed Patent). In such case, Licensee shall have the right to join such action as a party at its own expense using counsel of its
choice. Licensor shall be solely entitled to any and all recoveries resulting from such an enforcement action. Licensee shall have the sole right, but not the obligation, to bring suit against any Person for infringement or misappropriation of the
Licensed Patents within the Licensee Field, and to control such suit at its own expense. In such case, Licensor shall have (a) the right to join such action as a party at its own expense using counsel of its choice, and (b) the obligation
to join such action as a party to the extent necessary or reasonably useful to initiate or maintain such action at Licensee’s reasonable request and expense. Licensee shall be solely entitled to any and all recoveries resulting from such an
enforcement action. Licensor agrees to assist Licensee in any such legal proceedings, at Licensee’s reasonable request, and Licensee shall reimburse Licensor for all reasonable expenses incurred by Licensor in providing such assistance. Neither
party shall enter into any settlement or compromise of any action under this Section 5.02 that would in any manner diminish or otherwise adversely affect the other party’s rights under this Agreement without the prior
written consent of such other party, which consent shall not be unreasonably withheld, conditioned or delayed 
 ARTICLE VI. 

TERM 

Section 6.01    Term. This Agreement shall commence as of the Effective Date and shall
remain in effect in perpetuity. For the avoidance of doubt, in the event that Licensee shall be in material breach of this Agreement, then Licensor’s sole and exclusive remedy for such material breach shall be to seek damages, injunctive relief
or specific performance in accordance with Section 8.09, and in no event shall Licensor have the right to terminate this Agreement. 

Section 6.02    Survival. The provisions of this Section 6.02
and of Section 2.04 and Articles 1, 3, 4, 5, 7 and 8 shall survive any expiration of this Agreement. Upon expiration of this Agreement, the license granted to Licensee herein shall
immediately terminate, including all sublicenses granted by Licensee. 

  
 7 

 ARTICLE VII. 

RISK ALLOCATION 

Section 7.01    Indemnification by Licensee. Licensee will defend, indemnify and hold
harmless Licensor and its subsidiaries, parent corporations, affiliates, officers, directors, partners, employees, agents, successors and assigns (collectively, the “Licensor Indemnitees”) from and against any loss, damage, expense
(including reasonable attorney’s fees) or liability (“Losses”) arising from any third party claim, suit or proceeding (“Claims”) arising from or related to: (a) any breach of Licensee’s
representations, warranties or covenants under this Agreement; (b) the development, use, manufacture, exploitation, marketing, promotion, distribution, sale, export or import of any Licensed Products by Licensee, its Affiliates or its
sublicensees (or its or their respective agents, consultants or employees), and (c) any gross negligence or intentional misconduct by Licensee, its sublicensees (or its or their respective agents, consultants or employees) in performing its
obligations under this Agreement. The foregoing indemnification action shall not apply in the event and to the extent that such Losses or Claims arose as a result of any Licensor Indemnitee’s gross negligence, intentional misconduct or breach
of this Agreement or are Losses or Claims for which Licensor is responsible pursuant to Section 7.02 below. 

Section 7.02    Indemnification by Licensor. Licensor will defend, indemnify and hold
harmless Licensee and its subsidiaries, parent corporations, affiliates, officers, directors, partners, employees, agents, successors and assigns (collectively, the “Licensee Indemnitees”) from and against any Losses arising from
any Claim arising from or related to: (a) any breach of Licensor’s representations, warranties or covenants under this Agreement; (b) the development, use, manufacture, exploitation, marketing, promotion, distribution, sale, export or
import of any products practicing any Licensed Patents or other Licensed Business Intellectual Property by Licensor, its Affiliates or its or their licensees or sublicensees (or their respective agents, consultants or employees), and (c) any
gross negligence or intentional misconduct by Licensor, its Affiliates or its or their licensees or sublicensees (or their respective agents, consultants or employees) in performing its obligations under this Agreement. 

Section 7.03    Limitation of Liability. WITHOUT LIMITING THE INDEMNIFICATION OBLIGATIONS
IN SECTION 7.01 AND SECTION 7.02, AND EXCEPTING BREACHES OF ARTICLE IV AND EACH PARTY’S FRAUD AND INTENTIONAL MISCONDUCT, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL,
SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES OR ANY OTHER DAMAGES WHATSOEVER IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY. 

  
 8 

 ARTICLE VIII. 

MISCELLANEOUS 

Section 8.01    Relationship of Parties. For the purposes of this Agreement, each party
hereto shall be, and shall be deemed to be, an independent contractor and not an agent, partner, joint venturer, representative or employee of the other party. Neither party shall have authority to make any statements, representations, compromises
of rights or commitments of any kind, assume or create any obligations, or to accept process for or take any other action which shall be binding on the other party, except as may be explicitly provided for herein or authorized in writing by the
other party. 
 Section 8.02    Publicity. Neither party shall use any word, name,
logo, image, symbol, slogan, sample or design of the other party or the other party’s product, or any quote or statement from an employee, consultant or agent of the other party, in any written or oral advertisement, endorsement or other
promotional materials without the prior written approval of an authorized representative of the other party or as otherwise contemplated under this Agreement or another agreement between the parties, such approval not to be unreasonably withheld,
conditioned or delayed. 
 Section 8.03    Notices. All notices, requests, claims,
demands and other communications hereunder shall be in writing and shall be given (and shall be deemed to have been duly given upon receipt) by delivery in person or facsimile, (received by the Person to which it is addressed prior to 5 p.m., local
time, on a business day for such Person) or by registered or certified mail (postage prepaid, return receipt requested) or by recognized overnight courier service to the respective parties at the following addresses (or at such other address for a
party as shall be specified in a notice given in accordance with this Section 8.03): 
 if to Licensor: 

Boston Scientific Corporation 

300 Boston Scientific Way 

Marlborough, Massachusetts 01752 

Attention: Chief Financial Officer 

with copies (which shall not constitute notice) to: 

Boston Scientific Corporation 

300 Boston Scientific Way 

Marlborough, Massachusetts 01752 

Attention: Chief Corporate Counsel 

and 
 Latham & Watkins
LLP 
 200 Clarendon Street, 27th Floor 

  
 9 

 Boston, Massachusetts 02116 

if to Licensee: 
 Minerva
Surgical, Inc. 
 101 Saginaw Drive 

Redwood City, California 94063 

Attention: CEO 
 with a copy
(which shall not constitute notice) to: 
 Wilson Sonsini Goodrich & Rosati P.C. 

650 Page Mill Road 
 Palo Alto,
California 94304 
 Section 8.04    Severability. If any term or other provision of
this Agreement is invalid, illegal or incapable of being enforced by any rule of applicable law, or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or
legal substance of the transactions contemplated by this this Agreement is not affected in any manner materially adverse to any party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the
parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated by this Agreement be
consummated as originally contemplated to the fullest extent possible. 

Section 8.05    Entire Agreement; Assignment. This Agreement and each of the exhibits and
schedules hereto, together with the Transaction Documents, constitutes the entire agreement among the parties with respect to the subject matter hereof and supersede all prior agreements and undertakings, both written and oral, among the parties, or
any of them, with respect to the subject matter hereof. This Agreement shall not be assigned or transferred by either party without the prior written consent of the other party, such consent not to be unreasonably withheld, conditioned or delayed,
except that either party may assign this Agreement without the other party’s consent to (a) any Affiliate; or (b) a third Person that acquires all of its capital stock, or substantially all of its business or assets to which this
Agreement relates, whether by merger, acquisition, change of control or otherwise. No such assignment or transfer will be valid and effective unless and until the assignee agrees in writing to be bound by the provisions of this Agreement. Except as
expressly provided in this Section 8.05, any attempted assignment or transfer of this Agreement will be null and void. 

  
 10 

 Section 8.06    Parties in Interest.
This Agreement shall be binding upon and inure solely to the benefit of each party hereto and its respective successors and permitted assigns and, except as specifically contemplated or required herein, nothing in this Agreement, express or implied
is intended to or shall confer upon any other Person any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. 

Section 8.07    Specific Performance. Except as otherwise provided herein, any and all
remedies herein expressly conferred upon a party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by Law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise
of any other remedy. The parties hereto agree that irreparable damage may occur in the event any provision of this Agreement was not performed in accordance with the terms hereof and that the parties shall be entitled to seek specific performance of
the terms hereof, in addition to any other remedy at law or equity. 

Section 8.08    Governing Law. This Agreement shall be governed by, and construed in
accordance with, the laws of the State of Delaware applicable to contracts executed in and to be performed in that state, without regard to any conflicts of law principles that may apply. 

Section 8.09    Consent to Jurisdiction; Waiver of Jury Trial. 

(a)    EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE COURTS OF THE
STATE OF DELAWARE AND TO THE JURISDICTION OF THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE, FOR THE PURPOSE OF ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT AND EACH OF LICENSOR AND LICENSEE HEREBY IRREVOCABLY
AGREES THAT ALL CLAIMS IN RESPECT TO SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED EXCLUSIVELY IN ANY DELAWARE STATE OR FEDERAL COURT. EACH OF THE PARTIES HERETO AGREES THAT A FINAL JUDGMENT IN ANY ACTION OR, PROCEEDING SHALL BE CONCLUSIVE
AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW. 

(b)    EACH OF THE PARTIES HERETO IRREVOCABLY CONSENTS TO THE SERVICE OF THE SUMMONS AND COMPLAINT AND ANY OTHER PROCESS
IN ANY OTHER ACTION OR PROCEEDING RELATING TO THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, ON BEHALF OF ITSELF OR ITS PROPERTY, BY THE PERSONAL DELIVERY OF COPIES OF SUCH PROCESS TO SUCH PARTY. NOTHING IN THIS SECTION 8.09 SHALL AFFECT
THE RIGHT OF ANY PARTY TO SERVE LEGAL PROCESS IN ANY OTHER MANNER PERMITTED BY LAW. 
 (c)    EACH OF THE PARTIES HERETO
HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY
THIS AGREEMENT OR RELATED OR 

  
 11 

 
INCIDENTAL TO THE DEALINGS OF THE PARTIES IN RESPECT OF THIS AGREEMENT, IN EACH CASE, WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY, OR OTHERWISE. EACH PARTY
HEREBY FURTHER AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY AND THAT THE PARTIES MAY FILE A COPY OF THIS AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE
PARTIES TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY. EACH OF THE PARTIES HERETO HEREBY (I) CERTIFIES THAT NO REPRESENTATIVE OF THE OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF
LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, AND (II) ACKNOWLEDGES THAT IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, AS APPLICABLE, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND
CERTIFICATIONS IN THIS SECTION 8.09. 
 Section 8.10    Headings. The
descriptive headings contained in this Agreement are included for convenience of reference only and shall not affect in any way the meaning or interpretation of this Agreement. 

Section 8.11    Counterparts. This Agreement may be executed and delivered (including by
facsimile transmission or .pdf) in two (2) or more counterparts, and by the different parties hereto in separate counterparts, each of which when executed and delivered shall be deemed to be an original but all of which taken together shall
constitute one and the same agreement. 
 Section 8.12    Amendment. This Agreement may
not be amended except by an instrument in writing signed by Licensor and Licensee. 

Section 8.13    Waiver. Either party to this Agreement may (a) extend the time for
the performance of any of the obligations or other acts of the other party, (b) waive any inaccuracies in the representations and warranties of the other party contained herein or in any document delivered by the other party pursuant hereto, or
(c) waive compliance with any of the agreements of the other party or conditions to such party’s obligations contained herein. Any such extension or waiver shall be valid only if set forth in an instrument in writing signed by the party to
be bound thereby. Any waiver of any term or condition shall not be construed as a waiver of any subsequent breach or a subsequent waiver of the same term or condition, or a waiver of any other term or condition of this Agreement. The failure of
either party hereto to assert any of its rights hereunder shall not constitute a waiver of any of such rights. 

Section 8.14    Construction. 

(a)    Unless the context of this Agreement otherwise requires, (i) words of any gender include each other gender;
(ii) words using the singular or plural number also include the plural or singular number, respectively; (iii) the terms “hereof,” “herein,” “hereby” and derivative or similar words refer to this entire
Agreement; (iv) the terms “Section”, “Schedule” and “Exhibit” refer to the specified section of, or schedule or exhibit to, this Agreement; (v) the words “including,” “include” and
“includes” shall be deemed to be followed by the words “without limitation”; and (vi) the word “or” shall be disjunctive but not exclusive. 

  
 12 

 (b)    References to agreements and other documents shall be deemed to
include all subsequent amendments and other modifications thereto. References to statutes shall include all regulations promulgated thereunder and references to statutes or regulations shall be construed as including all statutory and regulatory
provisions consolidating, amending or replacing the statute or regulation. 
 (c)    The language used in this Agreement
shall be deemed to be the language chosen by the parties to express their mutual intent, and no rule of strict construction shall be applied against either party. 

(d)    Whenever this Agreement refers to a number of days, such number shall refer to calendar days unless business days
are specified and shall be counted from the day immediately following the date from which such number of days are to be counted. 
 [The
remainder of this page is intentionally left blank.] 

  
 13 

 IN WITNESS WHEREOF, and intending to be legally bound hereby, the parties hereto have caused
this Agreement to be duly executed and delivered as a sealed instrument by their duly authorized representatives as of the Effective Date. 
  

			
	BOSTON SCIENTIFIC CORPORATION

 
			
		
	By:	 	/s/ Vance Brown

 
			
	Name: Vance Brown
	Title: Vice President and Chief Corporate Counsel

  

			
	MINERVA SURGICAL, INC.

 
			
		
	By:	 	/s/ David Clapper

 
			
	Name: David Clapper
	Title: President and Chief Executive Officer

 Signature Page to Exclusive License Agreement (Seller to Buyer)EX-10.11

 Exhibit 10.11 

CERTAIN CONFIDENTIAL INFORMATION, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE (I) IT IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY
AND ACTUALLY TREATS THE INFORMATION AS PRIVATE AND CONFIDENTIAL. 
 SUPPLY AGREEMENT 

This SUPPLY AGREEMENT (this “Agreement”) is entered into as of May 11, 2020 (the “Effective
Date”) by and between MINERVA SURGICAL, INC., a Delaware corporation (“Buyer”), and BOSTON SCIENTIFIC CORPORATION (“Seller”). 

WHEREAS, Seller and Buyer have entered into a certain Asset Purchase Agreement dated as of April 28, 2020 (the
“Purchase Agreement”) pursuant to which Buyer is acquiring certain assets from Seller; 
 WHEREAS, the Purchase
Agreement requires the execution and delivery of this Agreement by Buyer and Seller; 
 WHEREAS, Buyer desires that Seller manufacture and
supply certain Products to Buyer on the terms set forth herein following the consummation of the transactions contemplated by the Purchase Agreement; 

WHEREAS, Seller is willing to manufacture and supply such Products to Buyer, all on the terms and conditions set forth herein; and 

WHEREAS, contemporaneously with this Agreement, Seller and Buyer entered into a certain Transition Services Agreement (the “Transition
Services Agreement”) pursuant to which Seller will perform certain services on behalf of Buyer. 
 NOW, THEREFORE, in consideration
of the premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by each of the parties hereto, Buyer and Seller agree as follows: 

1.    Definitions. For purposes of this Agreement, the following initially capitalized terms shall have the meanings set forth
below. Initially capitalized terms used herein and not otherwise defined shall have the meanings assigned thereto in the Purchase Agreement. 

A.    “CAPA” means a Corrective and Preventative Action in accordance with QSR and
applicable quality procedures of Seller and Buyer. 
 B.    “cGMP” means the
then-current Good Manufacturing Practices as defined by the FDA in Title 21 of the Code of Federal Regulations. 
 C.
    “Complaint” means any written, electronic or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness or performance of a Product after it
is released for distribution (i.e. is marketed and readily available for sale). 
 D.
    “Complaint Investigation” means a documented process for determining the root cause (or the most probable cause) of a Complaint.  

E.    “Confidential Information” means any and all information disclosed by or on behalf
of a party or any of its Representatives (“Disclosing Party”) to the other Party or any 

  
 1 

 
of its Representatives (“Receiving Party”) under or in connection with this Agreement, except information which is: (i) at the time of disclosure, or thereafter becomes, a
part of the public domain through no act or omission by Receiving Party or its Representatives; (ii) lawfully in the possession of Receiving Party prior to disclosure by or on behalf of Disclosing Party as shown by Receiving Party’s
written records (other than by virtue of being a Purchased Asset); (iii) lawfully disclosed to Receiving Party by a third party which did not acquire the same under an obligation of confidentiality from or through Disclosing Party, as shown by
written records; or (iv) independently developed by Receiving Party without use of Disclosing Party’s Confidential Information as shown by Receiving Party’s written records. As used herein, by example and without limitation,
“Confidential Information” shall mean any information of a party intended or marked as confidential, proprietary or privileged, which may include: (a) any and all technical information relating to the design, operation, testing, test
results, development, and manufacture of any party’s product (including, but not limited to, product specifications and documentation; engineering, design, and manufacturing drawings, diagrams, and illustrations; assembly code, software,
firmware, programming data, pseudocode, databases, and all information referred to in the same); product costs, margins and pricing; as well as product marketing studies and strategies; (b) information, documents and materials relating to a
party’s financial condition, management and other business conditions, prospects, plans, procedures, infrastructure, security, information technology procedures and systems, and other business or operational affairs; (c) any information
designated as pertaining to Intellectual Property, a trade secret or patentable invention; and (d) any other data or documentation resident, existing or otherwise provided in a database or in a storage medium, permanent or temporary, intended
for confidential, proprietary or privileged use by a party. 
 F.    “EEO Laws” means
Executive Order 11246, the Vietnam Era Veterans Readjustment Assistance Act, Section 503 of the Vocational Rehabilitation Act, and their implementing regulations. 

G.    “FDA” means the United States Food and Drug Administration, or any successor agency
thereto. 
 H.    “Medical Device Report” or “MDR” means a report filed
with the FDA to communicate an event when Buyer or Seller “becomes aware” (as defined in Title 21 of the Code of Federal Regulations, Part 803.3) of information that reasonably suggests that a Product: 

(a) may have caused or contributed to a death, serious injury or serious deterioration in the state of health of a user or
patient; or 
 (b) has malfunctioned (as defined in Title 21 of the Code of Federal Regulations, Part 803.3) and that such
Product would be likely to cause or contribute to a death or serious injury of a user or patient if the malfunction were to recur. 

I.     “Medical Device Vigilance Report” or “MDV” means the official
notification provided to Regulatory Authorities outside of the United States of adverse events deemed reportable pursuant to the local laws and/or regulations. 

J.     “Product(s)” means the finished good(s) referred to on Schedule A. 

  
 2 

 K.    “QSR” means the Quality System
Regulation as defined by the FDA in Title 21 of the Code of Federal Regulations, Part 820. 
 L.
    “Recall” means a removal or correction of a Product that a Regulatory Authority would consider to be in violation of the Laws it administers and against which the Regulatory Authority would initiate legal
action. 
 M.     “Regulatory Authority” means any national, supra-national, regional,
state or local regulatory agency, department, bureau, notified bodies, commission, council or other governmental entity having jurisdiction over the territory in which Buyer may sell the Products, including the FDA. 

N.     “Representatives” means a Person’s employees, officers, directors, affiliates,
subcontractors, agents, successors and assigns. 
 O.    “Specifications” means the
specifications set forth in the part number and revision level controlled drawing for the applicable Product that are referenced on the purchase and/or blanket order at the time of issuance of such order. 

2.    Purchase and Sale. 

2.1.    Supply of Products. Seller shall manufacture and supply the Products to Buyer on the terms and conditions
set forth in this Agreement. 
 2.2.    Orders. Buyer shall order Products by using its form purchase order;
provided that the terms of this Agreement shall supersede any conflicting terms in any such purchase orders. 

2.3.    Shipping; Freight Terms. Seller shall deliver Products in accordance with Buyer’s instructions to the
location specified in the purchase order. Except as set forth in any SLA (as defined below), title to the Products shall pass to Buyer upon delivery by Seller to Buyer’s appointed carrier. Seller shall deliver all Products to Buyer free and
clear of all liens and encumbrances or other defects in title. All Products shall be shipped F.C.A. (Incoterms 2020) Buyer’s designated shipping point. Risk of loss and damage shall pass to Buyer upon delivery by Seller to Buyer’s
appointed carrier. All shipping charges are at the expense of Buyer. 
 2.4.     Inventory; Scheduling. Buyer shall provide
Seller with a non-binding, rolling 12-month forecast, updated each month, on or by the fifth business day of the month. Promptly following the Effective Date, Buyer will
submit its first forecast and a purchase order (each, a “Purchase Order”) for the first three months of the term of this Agreement. Thereafter, Buyer will submit, on a monthly basis, a forecast and a Purchase Order for the Products
to be delivered in the third month of such forecast. The quantity of Products set forth in any Purchase Order for any month will be as agreed by both parties based on plant and supplier capacity and lead times. Seller shall deliver Products in
accordance with the delivery schedules set forth in the applicable Purchase Order. Buyer may not cancel any Purchase Order without Seller’s prior written consent. Upon signing of this Agreement or in the future, Seller and Buyer may enter into
individual service level agreements relating to inventory management (e.g. kanban, consignment, etc.) (referred to herein as “SLAs”). Any SLA between Seller and Buyer(s) shall be incorporated by reference into this Agreement. 

  
 3 

 2.5    Vendors. Seller shall have the right to engage vendors for the performance
of its activities under this Agreement; provided that Seller shall remain responsible and liable for its vendors’ compliance with the terms of this Agreement, including all relevant restrictions, limitations and obligations. With respect to the
engagement by Seller of any new vendors after the Effective Date, Seller shall provide Buyer a reasonable opportunity to object to the selection or discharge of such vendors, and Seller shall take into consideration Buyer’s objections in good
faith. 
 2.6     Transition Services Agreement. In the event of a conflict between any term or condition of this Agreement and
any term or condition of the Transition Services Agreement with respect to the manufacture and supply of Products, such term or condition of the Transition Services Agreement will govern, solely to the extent of such conflict. 

3.    Pricing; Payment. 

3.1.    Pricing. Product prices throughout the term of this Agreement for the Product(s) shall be those set forth
in Schedule A and include all packaging and other charges. Such pricing is the total compensation due Seller under this Agreement, and no other compensation is or will be due Seller. All amounts due and payable to Seller hereunder shall be
exclusive of applicable sales, excise (including any excise tax imposed on the sale of certain medical devices) and similar taxes. Buyer shall be responsible for the payment of all such taxes (excluding taxes based upon Seller’s income) and
shall provide Seller with all documentation reasonably requested by Seller to confirm Purchaser’s payment of such excise tax. 

3.2.    Payment. 

A.    Payment will be due 30 days from Buyer’s receipt of an applicable invoice, unless Buyer in good faith disputes
all or any portion of the invoice, in which case Buyer will be obligated to pay the undisputed portion of the invoice by such date. However, if the invoice date is prior to shipment of the applicable Products, the 30 days shall instead be calculated
from the shipment date. Seller shall invoice Buyer promptly (but not later than 30 days) after shipment of the applicable Product. 

B.    Any past due amounts payable under this Agreement will be subject to a late fee of one percent (1%) per month or the
highest rate allowed by applicable Law, whichever is less. 
 4.     Quality Assurance; Recordkeeping; Notification. The
following obligations of Seller set forth in Sections 4.1 through 4.13 shall be collectively referred to throughout this Agreement as the “QA Standards”. 

4.1. Changes. 
 A. If
Seller desires to make any change in Seller’s processing or handling of Product, the Specifications, processing, composition, formulation, part or supplier of a raw material or component comprising or included in a Product, or the manufacturing
process or handling processes for, or performance characteristics of any Product or any part thereof (including materials, packaging, labeling and Directions for Use, shipping, documentation, etc.) and such change would require a revision to the
Device Master Record (DMR) via an Engineering Change Order (ECO), Document Change Notice (DCN) or the like, an internal regulatory filing (e.g., a letter to file) or an external filing submission to a Regulatory Authority, Seller shall provide prior
notice to Buyer, including the details regarding such proposed change or action, a sample of the affected Product and such other information reasonably requested by Buyer. All such changes or 

  
 4 

 
actions shall be submitted in writing to Buyer no later than 45 days prior to Seller’s proposed date of implementation for such change. Seller shall not implement any such change or action
without Buyer’s prior written approval. If such a proposed change is approved by Buyer, Seller shall be responsible for properly communicating and implementing such change, including with respect to any of Seller’s vendors. 

B. In addition to the foregoing, if Seller desires to make any change in Seller’s location of manufacturing of the Products, Seller shall
provide prior notice to Buyer, including the details regarding such proposed change, and such other information requested by Buyer. All such changes shall be submitted in writing to Buyer no later than 12 months prior to Seller’s proposed date
of implementation for such change. Seller shall not implement any change in the location of manufacturing of any Product without Buyer’s prior approval, which may be granted or withheld in Buyer’s sole discretion.  

C. If Buyer desires a change to the Specifications that affects Seller’s processing or handling of Product, the Specifications,
processing, composition, formulation, part or supplier of a raw material or component comprising or included in a Product, or the manufacturing process or handling processes for, or performance characteristics of any Product or any part thereof
(including materials, packaging, labeling and Directions for Use, shipping, documentation, etc.), and the cost to Seller to implement such change is greater than $5,000, Buyer shall be responsible for reasonable costs incurred by Seller to implement
such changes, as mutually agreed in good faith by the parties. 
 4.2.    Product Warranty. Seller represents and
warrants to Buyer that, upon delivery of Product to the shipping agent, each Product shall: (i) conform to the Specifications; (ii) consist only of new materials (unless otherwise specified); and (iii) comply with applicable Laws
relating to the manufacture, packaging, labeling and sale of the Products. EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, SELLER’S SOLE LIABILITY TO BUYER, AND BUYER’S EXCLUSIVE REMEDY FROM SELLER, FOR BREACH OF THESE PRODUCT WARRANTIES
SHALL BE CREDIT OR REPLACEMENT OF THE NONCONFORMING PRODUCT. 
 4.3.    Manufacturing Conformity. Seller shall
manufacture, store and handle the Products in accordance with (i) all applicable Laws and regulations relating to the manufacturing, packaging, labeling and sale of the Products, including cGMP, QSR, ISO 13485 and ISO 14971 requirements,
Medical Device Directive (“MDD”) requirements, CMDCAS requirements, and other pertinent rules and regulations of the FDA and other similar Regulatory Authorities in other applicable jurisdictions; and (ii) Seller’s
standard quality assurance policies. During the term of this Agreement, Seller shall maintain or cause to be maintained the Product manufacturing facility’s registration as a certified medical device manufacturing facility and shall maintain
such facility registration with all applicable Regulatory Authorities or cause such facility to be maintained such that the facility would pass an audit for compliance with cGMP and QSR. Seller shall maintain ongoing quality assurance and testing
policies sufficient to satisfy its obligations under this Agreement. Buyer shall be responsible for obtaining any required regulatory registrations, including ISO registration for Products under Buyer’s notified body or through other applicable
Regulatory Authorities. 
 4.4.    Product Acceptance. Each shipment of Product from Seller to Buyer shall be
inspected by Seller prior to shipment. All Products are subject to final inspection and acceptance 

  
 5 

 
by Buyer or its designee within 60 days of delivery. Buyer shall notify Seller within 60 days of delivery of any apparent defective material or workmanship or
non-conformity of any Product to the Specifications or purchase order. If Buyer fails to notify Seller within 60 days of delivery of an apparent defect, Buyer shall be deemed to have accepted the
Product; provided, that the warranty contained in Section 4.2 shall survive such acceptance. Buyer shall have the right to reject any Product that is not in conformity with the warranty contained in Section 4.2. Any item that has been
rejected must be credited or replaced by and at the expense of Seller promptly after notice. Buyer shall return all rejected Products to Seller at Seller’s expense. Seller shall investigate the cause for the rejection and, within a
reasonable period of time (not to exceed 30 days), provide to Buyer in writing all proposed corrective actions associated with the cause for rejection. Notwithstanding anything stated herein to the contrary, no rejection shall be made past the
expiration date (if any) of any Product. 
 4.5. Complaints; Corrective Action. 

A.Promptly after Seller’s receipt from a third party of a Complaint, Seller shall provide Buyer with a copy of such Complaint. As needed,
Buyer may require Seller to assist with Complaint Investigations to investigate the cause of any Complaints and to determine any required corrective actions, where the Product is deemed to be out of compliance with the Specifications. Within 30 days
after Seller’s receipt of a request from Buyer to perform a Complaint Investigation, Seller shall perform such Complaint Investigation and provide to Buyer a written report of such Complaint Investigation, including a root cause analysis and
corrective action recommendations. In the event the Complaint involves a Medical Device Report or Medical Device Vigilance Report, for a Product, Buyer may require Seller to expedite the Complaint Investigation in order to comply with any applicable
regulatory filing requirements. Seller shall maintain records of all such Complaint Investigations as required by cGMP and other applicable rules and regulations of any Regulatory Authority. 

B.    In accordance with Buyer’s quality management system, except as set forth in the Transition Services Agreement,
Buyer shall be responsible for entering all Complaints, as well as applicable analyses of Seller, into Buyer’s Complaint handling system. If Buyer desires Seller to assist with corrective actions, Buyer will return to Seller the Product that is
the subject a Complaint if such Product has been made available to Buyer. Seller will maintain a cross-reference from Seller’s Complaint response to Buyer’s associated Complaint file numbers.

C.     Seller will complete all corrective actions, including any corrective actions identified in a response to Buyer
pursuant to this Section and agreed to by Buyer or any corrective actions requested by Buyer, within 90 days or as mutually agreed to by Buyer and Seller via a Supplier Corrective Action Request (SCAR), and upon request of Buyer, provide written
certification of such completion.  
 D.    Except as set forth in the Transition Services Agreement,
Buyer shall be responsible for filing all required complaint reports relating to Products (including but not limited to MDR and or MDV reports) with the appropriate Regulatory Authorities. 

4.6.     Product Recalls. 

A.    If, in the judgment of Buyer, any defect or any government action requires a Recall of, or the issuance of an
advisory letter regarding, any Product, Buyer shall undertake such Recall or issue such advisory letter and shall manage such Recall. 

  
 6 

 B.In the event of a Recall of a Product found to be out of compliance with the
Specifications, Seller shall correct any deficiency relating to its manufacturing, packaging, testing, labeling, storing or handling of such Product, if applicable, or cause the vendor of any material, component, or
sub-assembly incorporated into such Product to do likewise with respect to such material, component, or sub-assembly. The reasonable costs incurred by each party in
connection with any Recall shall be borne by Buyer, unless the Recall is caused by (i) a breach of this Agreement by Seller including any representation, warranty, covenant or obligation hereunder, or (ii) manufacturing error by Seller or
any vendor or sub-vendor acting under its authority, including any breach or error resulting in or from a Product being out of compliance with the Specifications, in which case the reasonable costs incurred by
each party in connection with such Recall shall be borne by Seller. Without limiting the foregoing, in such instance when Seller is deemed to be responsible for the reasonable costs incurred by each party in connection with a Recall as further set
forth in this Section 4.6, Seller shall, at Buyer’s option, either: (i) at Seller’s sole cost and expense replace each unit of the Product involved in the Recall (including units held in inventory at Purchaser or its customers)
with a corrected Product within a reasonable period of time, or (ii) refund the purchase price thereof. 
 4.7.
    Inspection; Access. Seller shall provide Buyer and its Representatives (including external auditors and representatives of its notified body) with such documentation and access to facilities and personnel as Buyer may
reasonably request to conduct an initial and periodic inspection of such facilities and manufacturing procedures for compliance with the appropriate ISO standards, cGMP, QSR, the Specifications and Buyer’s quality assurance requirements, and to
inspect Seller’s inventory of Products, work-in-process, raw materials to be used in the Products, and other such matters as may be pertinent to proper quality
assurance of the Products. In accordance with applicable Laws and regulations governing regulatory inspections, Seller shall permit authorized representatives of relevant Regulatory Authorities, including the FDA, to inspect any plant and production
facilities relating to or used in connection with the manufacture of Product. Buyer shall give Seller a minimum of two business days’ prior notice for a “for cause” inspection or a minimum of 10 business days prior notice for any
routine inspection.    Seller shall use commercially reasonable efforts to take such action as is required to correct any deficiencies identified by Buyer relating to the production of any Product. Seller shall provide such
documentation or conduct such analyses as Buyer may reasonably request in connection with any regulatory submission or audit. 

4.8.    Seller’s Vendors. At Buyer’s request, Seller shall perform a quality system assessment of the
vendors who provide Seller with raw materials, components, sub-assemblies or contract services for any Products. Seller shall assist Buyer in arranging visits and inspection of the plants at which
Seller’s vendors manufacture any raw material, component or sub-assembly relating to a Product or any service relating to a Product is performed. 

4.9.    Records. For a period of the longer of seven years after delivery to Buyer of each Product, or such period
as may be required by cGMP and other applicable rules and regulations of any Regulatory Authority, Seller shall: (a) maintain traceability records for each Product, including the manufacture date and lot number of each unit of Product and each
component and material comprising Product; (b) maintain records subject to 21 CFR 820 Subpart M, such as the Device Master Record, quality system record, and Complaint files; and (c) provide Buyer a copy of such records without charge upon
Buyer’s reasonable request. 

  
 7 

 4.10.    Required Notification. Seller shall promptly notify
Buyer by electronic medium (fax or e-mail), with confirming notice via a nationally recognized overnight delivery service that guarantees overnight delivery and requires the signature of recipient, as soon as
Seller becomes aware of any: (a) defect or condition which renders or may render any Product ineffective or dangerous; (b) Product that is not in compliance with the Specifications (including manufacturing processes, labeling or packaging)
or any QA Standards; (c) any death or bodily injury caused by a Product (or suspected to be caused by a Product) or any malfunction of a Product; or (d) regulatory, FDA or ISO inspections and/or other communications with Regulatory
Authorities related to Product or that would in any way impact the Product or Seller’s performance of its responsibilities hereunder. 

4.11.    Quality Plan. Seller and Buyer shall establish a quality plan which shall define the quality practices,
the resources and the activities relevant to Products that are designed or manufactured for Buyer. Notwithstanding the foregoing, at Buyer’s request, the parties shall negotiate in good faith and enter into a separate quality agreement setting
forth the parties’ respective rights, responsibilities and obligations with respect to Product quality. 

4.12.    Compliance with Laws. Each party shall comply with all Laws and regulations applicable to the performance
of its obligations under this Agreement, including Laws and regulations pertaining to the testing, manufacture, labeling, packaging import, export, distribution, sales or marketing of the Products. 

4.13.    Packaging and Labeling. All Products shall be labeled (including bar coding/UPN numbers) in accordance
with the procedures specified from time to time by Buyer and Buyer shall have final approval over all packaging and labeling for Products. Buyer maintains the right to over label Products as it deems necessary but shall not utilize any trademarks of
Seller without Seller’s approval. Buyer is responsible for ensuring that all packaging and labeling materials, data, information, text, and graphics for use with the Products are in compliance with applicable Law and relevant regulatory
approvals. 
 4.14.    EEO Laws. Each party acknowledges that the other party is an equal employment
opportunity/affirmative action employer subject to the EEO Laws. By acceptance of this Agreement, each party certifies that it complies and will continue to comply with all applicable EEO Laws, and it shall not, amongst other things, discriminate on
the basis of race, age, color, religion, gender, sexual orientation, disability, veteran status, national origin or any other characteristic protected by federal, state or local Law. 

5.     Additional Representations and Warranties. Each party hereby represents and warrants to the other party that the
execution and delivery of and performance under this Agreement by such party does not, and will not, conflict with or violate any other agreement or obligations with third parties or any restrictions of any kind or any Law to which it is bound or
subject. 
 6.     Confidential Information; Intellectual Property.  

6.1.    Confidential Information. Article 8 of the Transition Services Agreement shall apply to Confidential
Information of each party disclosed or accessed under this Agreement, and is incorporated herein by reference. 
 6.2. Tangible
Property. All tangible property of one party provided to the other party in connection with this Agreement, including reports, communications, and analyses (collectively, “Tangible Property”), shall be and remain the
exclusive property of such party 

  
 8 

 
unless otherwise agreed in writing. Each party shall: (a) keep and maintain in its custody and subject to its control any Tangible Property that it receives during the term of this
Agreement; and (b) return or surrender to the other party all such party’s Tangible Property within 30 days after termination or expiration of this Agreement. For clarity, and notwithstanding the foregoing any and all tangible property
included in the Purchased Assets shall be and remain the exclusive property of Buyer. 
 6.3.    Intellectual
Property. Buyer hereby grants to Seller and its Affiliates a worldwide, royalty-free, limited right and license during the term of this Agreement to use the Business Transferred Intellectual Property, with the right to sublicense solely to
Seller’s vendors and sub-vendors, in each case, solely to the extent necessary to: (i) manufacture, test, label and package (and to have manufactured, tested, labeled and packaged) the Products
pursuant to the terms of this Agreement; and (ii) carry out any other obligations of Seller under this Agreement. The license provided by this Section 6.3 shall terminate upon the termination of this Agreement or, if earlier, the date on
which Seller and its vendors and sub-vendors are no longer manufacturing Products for Buyer. 
 7.
    Insurance and Indemnification.  
 7.1.    Insurance. Seller and Buyer
shall each maintain the following insurance in amounts adequate to satisfy its respective insurable obligations under this Agreement: (a) Commercial General Liability; and (b) Workers Compensation insurance or permitted self-insurance as
required by statute. At any time upon the reasonable request of the other party, each party shall provide a certificate(s) of insurance as evidence that the required insurance is in effect. 

7.2.    Indemnification. 

A.    Seller shall indemnify, defend and hold harmless Buyer, its Affiliates and their respective Representatives for any
and all damages, expenses and losses, including reasonable attorneys’ fees, arising from third party claims, actions or proceedings (“Claims”) resulting from or relating to: (i) the willful misconduct, gross negligence,
fraud or violation of Law by Seller or its Representatives in the performance of, or its or their failure to perform, any of Seller’s obligations under this Agreement; or (ii) any breach of Seller’s representations, warranties,
covenants or obligations under this Agreement; except in each case (i) and (ii) to the extent that Buyer is responsible for such Claim pursuant to Section 7.2.B. 

B.     Buyer shall indemnify, defend and hold harmless Seller, its Affiliates and their respective Representatives for any
and all Claims resulting from or relating to: (i) any personal injury or property damage resulting from or caused by any Product following delivery to Buyer’s appointed carrier, (ii) the willful misconduct, gross negligence, fraud or
violation of Law by Buyer or its Representatives in the performance of, or its or their failure to perform, any of Buyer’s obligations under this Agreement; or (iii) any breach of Buyer’s representations, warranties, covenants or
obligations under this Agreement; except in each case (i)-(iii) to the extent that Seller is responsible for such Claim pursuant to Section 7.2.A. 

C.     Each party’s obligations to the other party under this Section 7.2 are conditioned upon the party seeking
indemnification: (i) providing notice to the indemnifying party of any Claims promptly, but not later than 30 days, after the party knows of such Claim, provided that delay or failure to provide such notification shall not affect the
indemnification provided under 

  
 9 

 
this Section 7.2 except to the extent the indemnifying party has been actually prejudiced as a result of such delay or failure; (ii) permitting the indemnifying party to assume full
responsibility for the defense of such Claim, provided that the indemnifying party shall not enter into any settlement that admits fault, wrongdoing or damages without the indemnified party’s prior written consent; (iii) assisting the
indemnifying party in defense of such Claim; and (iv) not compromising or settling any such Claim without the indemnifying party’s prior consent. The indemnified party shall have the right to participate, at its own expense and with
counsel of its choice, in the defense of any Claim that has been assumed by the indemnifying party. 

D.    Notwithstanding anything herein to the contrary, neither party shall be entitled to make a claim for indemnification
under both this Agreement and the Purchase Agreement with respect to the same damages that are related to or arise, directly or indirectly, out of a particular event, circumstance or loss. 

E.    EXCEPT WITH REGARD TO THE WILLFUL MISCONDUCT, GROSS NEGLIGENCE OR FRAUD OF A PARTY, IN NO EVENT WILL SELLER’S
LIABILITY TO BUYER UNDER THIS AGREEMENT, OR BUYER’S LIABILITY TO SELLER UNDER THIS AGREEMENT, EXCEED THE TOTAL AMOUNTS REASONABLY EXPECTED TO BE PAID OR PAYABLE BY BUYER TO SELLER IN RESPECT OF THE PRODUCTS. 

F.    EXCEPT WITH REGARD TO BREACHES OF ARTICLE 6 OR THE WILLFUL MISCONDUCT, GROSS NEGLIGENCE OR FRAUD OF A PARTY, AND
WITHOUT LIMITING EITHER PARTY’S INDEMNIFICATION OBLIGATIONS UNDER THIS ARTICLE 7, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT FOR ANY AMOUNTS REPRESENTING LOST PROFITS,
PUNITIVE DAMAGES, OR FOR ANY OTHER INDIRECT, SPECIAL, INCIDENTAL, OR CONSEQUENTIAL DAMAGE, EVEN IF THEY WERE FORESEEABLE OR SUCH PARTY HAD BEEN INFORMED OF THEIR POTENTIAL. 

8.     Remedies; Dispute Resolution. Any Dispute shall be resolved in accordance with the procedures set forth in the Purchase
Agreement, which shall be the sole and exclusive procedures for the resolution of any such Dispute unless otherwise specified herein or in the Purchase Agreement and are incorporated herein by reference. 

9.    Term.  

9.1.     Term; Termination. 

A.    The term of this Agreement shall commence on the Effective Date and, unless terminated earlier in accordance with
this Article 9, continue in full force and effect until the expiration or termination of the Transition Services Agreement. 

B.    This Agreement may be terminated earlier as set forth in Section 9.2 or as follows: 

(i)    by Buyer without cause, upon at least 90 days’ prior written notice to Seller; 

(ii)     60 days after notice of breach from Buyer to Seller, but only if such breach remains uncured
at the end of such 60-day period; 

  
 10 

 (iii)     60 days after notice of breach from
Seller to Buyer, but only if such breach remains uncured at the end of such 60-day period; or 

(iv)     immediately upon notice from a party if the other party has become the subject of a voluntary or
involuntary bankruptcy, receivership, or insolvency proceeding that is not stayed or dismissed within 90 days of filing. 

C.    All obligations which are by their nature continuing, including the obligations contained in Sections 4.5, 4.6, 4.7,
4.8, 4.9, 4.10, 9.2, 10.4 and Articles 6 through 8, shall survive the expiration or termination of this Agreement. All other rights and obligations shall terminate upon the expiration of termination of this Agreement. 

D.    Buyer may remove a particular Product(s) from this Agreement effective at any time, upon at least 90 days’
prior written notice to Seller, which notice shall specify which Products are being removed. 
 9.2.    Force
Majeure. If a party’s performance is delayed because of war or similar unrest, fire, act of God or other similar cause that is beyond its control and which such party could not have reasonably prevented, such delay in performance shall not
be considered a breach of this Agreement; provided, however, that if such delay continues for 60 days or more, then: (a) any Buyer may upon notice cancel all or any portion of its unfilled orders; and (b) Buyer may immediately terminate
this Agreement upon notice to Seller. The party affected by such force majeure event will provide the other party with full particulars thereof as soon as it becomes aware of the same (including its best estimate of the likely extent and duration of
the interference with its activities), and will use its commercially reasonable efforts to overcome the difficulties created thereby and to resume performance of its obligations as soon as practicable. 

9.3.    Fulfillment Upon Termination. Upon termination or expiration of this Agreement: (i) Seller shall be
obligated to fulfill any open Purchase Orders, and (ii) Buyer shall be obligated to purchase all Products subject to such open Purchase Orders, subject to the terms of this Agreement, except as set forth in any SLA or if termination of this
Agreement is due to Seller’s breach of this Agreement. 
 9.4.    Excess Material, Components, WIP, Etc.
Upon expiration or termination of this Agreement, Seller shall deliver to Buyer, and Buyer shall purchase from Seller at cost, all raw material and components used in the Products, and work in progress (i.e., WIP) and finished inventory of Products
that is held by Seller at the effective time of such expiration or termination. 
 10.    Miscellaneous. 

10.1.    Relationship of the Parties. The parties hereto are independent contractors and neither party is a
fiduciary, employee, partner, joint venture or agent of the other. Under no circumstances shall any of the employees of a party hereto be deemed to be employees of the other party for any purpose. Neither party shall have the right to bind the other
to any agreement with a third party nor to represent itself as a partner, joint venturer or agent of the other by reason of this Agreement. 

10.2.    Assignment. No assignment, pledge or other transfer of this Agreement or of any rights, interests or
obligations hereunder may be made by Buyer or Seller (by operation of Law or otherwise) without the prior written consent of the other party and any attempted assignment, pledge or transfer without the required consent shall be void. Such consent
shall not be 

  
 11 

 
unreasonably withheld, conditioned or delayed. No assignment, pledge or transfer of any obligations under this Agreement shall relieve the parties of any such obligations. Notwithstanding the
foregoing, (a) either party shall be entitled to assign this Agreement to such party’s Affiliates, provided that such party shall remain jointly and severally liable with such Affiliate for the performance of the obligations assumed
by such Affiliate, (b) Buyer shall be entitled to assign this Agreement following the Effective Date, to a third party acquiring all or substantially all of the Business or to any successor entity of Buyer in connection with a merger or sale of
substantially all the assets or capital stock of Buyer and (c) Seller shall be entitled to assign this Agreement following the Effective Date, to a third party acquiring all or substantially all of Parent’s urology and pelvic heath
division or to any successor entity of Parent in connection with a merger or sale of substantially all the assets or capital stock of Parent; provided that in the cases of (b) and (c), such third party agrees in writing to assume all
obligations of Buyer pursuant to this Agreement. 
 10.3.    Notices. Unless otherwise specifically provided
herein, all notices, requests, claims, demands and other communications hereunder shall be in writing and shall be given or made (and shall be deemed to have been duly given or made upon receipt) by delivery in person, by an internationally
recognized overnight courier service, by facsimile, by e-mail or by registered or certified mail (postage prepaid, return receipt requested) to the respective parties hereto at the following addresses (or at
such other address for a party as shall be specified in a notice given in accordance with this Section 10.3): 
  

			
	Seller:	  	with a copy to:
		
	 Boston Scientific Corporation
 300 Boston
Scientific Way
 Marlborough, MA 01752
 Attention: Chief
Financial Officer
	  	 Boston Scientific Corporation
 300
Boston Scientific Way
 Marlborough, MA 01752
 Attention: Chief
Corporate Counsel

		
	Buyer:	  	with a copy (which shall not constitute notice) to:
		
	 Minerva Surgical, Inc.
 4255 Burton Drive

Santa Clara, CA 95054
	  	 Wilson Sonsini Goodrich & Rosati P.C.

650 Page Mill Road
 Palo Alto, CA 94304

 All such notices, requests, demands, consents and other communications shall be deemed to have been duly given or sent three
(3) days following the date on which mailed, or one (1) day following the date mailed if sent by overnight courier, or on the date on which delivered by hand or by email or facsimile transmission (receipt confirmed), as the case may be,
and addressed as set forth above. 

  
 12 

 10.4.    Governing Law. This Agreement shall be governed by, and
construed in accordance with, the laws of the State of Delaware applicable to contracts executed in and to be performed in that state, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Delaware
or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware. 

10.5.    Entire Agreement. This Agreement, the Purchase Agreement and the Ancillary Agreements constitute the
entire agreement of the parties hereto with respect to the subject matter hereof and thereof and supersede all prior agreements and undertakings, both written and oral, between Seller and Buyer with respect to the subject matter hereof and thereof.

 10.6.    Amendment. This Agreement may not be amended or modified except (a) by an instrument in writing
signed by, or on behalf of, Buyer and Seller or (b) by a waiver in accordance with Section 10,8. 

10.7.    Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being
enforced by any Law or public policy, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect for so long as the economic or legal substance of the transactions contemplated by this Agreement is not
affected in any manner materially adverse to either party hereto. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement
so as to effect the original intent of the parties as closely as possible in an acceptable manner in order that the transactions contemplated by this Agreement are consummated as originally contemplated to the greatest extent possible. 

10.8.    Waiver. Either party to this Agreement may (a) extend the time for the performance of any of the
obligations or other acts of the other party, (b) waive any inaccuracies in the representations and warranties of the other party contained herein or in any document delivered by the other party pursuant hereto or (c) to the extent
permitted by applicable Law, waive compliance with any of the agreements of the other party or conditions to such party’s obligations contained herein. Any such extension or waiver shall be valid only if set forth in an instrument in writing
signed by the party to be bound thereby. Any waiver of any term or condition shall not be construed as a waiver of any subsequent breach or a subsequent waiver of the same term or condition, or a waiver of any other term or condition of this
Agreement. The failure of either party hereto to assert any of its rights hereunder shall not constitute a waiver of any of such rights. 

10.9.    Interpretive Rules. The words “hereof,” “herein” and “hereunder” and words
of similar import when used in this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement, and all Section references are to this Agreement unless otherwise specified. The words “include,”
“includes” and “including” will be deemed to be followed by the phrase “without limitation.” The word “days” means calendar days unless otherwise specified herein. The headings contained in this Agreement are
for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. No provision of this Agreement shall be construed to require a party or its respective officers, directors, or Affiliates to take any action
that would violate or conflict with any applicable Law. The word “if” means “if and only if.” The word “or” shall not be exclusive. The meanings given to terms defined herein will be equally applicable to both the
singular and plural forms of such terms. Whenever the context may require, any pronoun includes the corresponding 

  
 13 

 
masculine, feminine and neuter forms. Except as otherwise expressly provided herein, all references to “dollars” or “$” will be deemed references to the lawful money of the
United States of America. 
 10.10.    Counterparts. This Agreement may be executed in any number of counterparts
and by the Parties in separate counterparts, and delivered by facsimile or other means of electronic transmission (including by .PDF format), each of which shall be deemed to be one and the same instrument and an original document. 

10,11    No Third Party Beneficiaries. This Agreement shall be binding upon and inure solely to the benefit of the
parties hereto and their respective successors and permitted assigns and nothing herein is intended to or shall confer upon any other Person any legal or equitable right, benefit or remedy of any nature whatsoever, including any rights of employment
for any specified period, under or by reason of this Agreement. 
 [Signature Page Follows] 

  
 14 

 IN WITNESS WHEREOF, the parties have caused their duly authorized representatives to execute
this Agreement as of the Effective Date. 
  

									
	MINERVA SURGICAL, INC.	 		 	                          BOSTON SCIENTIFIC
CORPORATION

									
					
	By	 	 /s/ David Clapper
	 		 	By	 	 /s/ Vance Brown

									
		 	(Signature)	 		 		 	(Signature)

									
					
	Print Name:	 	 David Clapper
	 		 	Print Name:	 	 Vance Brown

									
					
	Title:	 	 President and Chief Executive Officer
	 		 	Title:	 	 Vice President and Chief Corporate Counsel

  
 15 

 SCHEDULE A: SUPPLY AGREEMENT – PRODUCTS AND PRICING 

[***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}]]